We have cloned, expressed, and partially purified a naturally occurring, truncated, soluble form of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor a subunit to investigate its biochemical and biologic properties. The soluble receptor species lacks the transmembrane and cytoplasmic domains that are presumably removed from the intact receptor cDNA by a mechanism of alternative splicing. The resulting soluble 55-to 60-kD glycosylated receptor species binds GM-CSF with a dissociation constant (kd) of 3.8 nmol/L. The soluble GM-CSF receptor HE PROLIFERATION AND differentiation of hematopoietic progenitors and many of the functions of mature hematopoietic elements are dependent on the presence of hematopoietic cytokines. The cytokines initiate their biologic effects by binding to highly specific cell-surface cytokine receptors. The receptors function as multisubunit complexes. Cloning of the cDNAs encoding many of the receptor subunits has shown that they constitute a cytokine receptor superfamily.' It has also become clear that a substantial number of the cytokine receptor subunits exist in a naturally occurring soluble form.' Most of these soluble receptor forms arise as the result of alternative splicing events,"' but cleavage of the extracellular domains of the interleukin-6 receptor (IL-6R) a chain and the ciliary neurotrophic factor receptor (CNTFR) a chain from the surface of cells can also give rise to soluble receptor variants in those two sy~tems.',~
forming assay and, thus, may be able to modulate GM-CSF function in vivo.
MATERIALS AND METHODS
Cloning and expression of GMRsol and GMRtm. GMRsol and GMRtm were cloned from a h-gtl 1 human placenta cDNA library (Clonetech Inc, Palo Alto, CA) screened with synthetic oligonucleotides corresponding to published GMRtm subunit sequence.y The cDNA sequence containing the open reading frame of GMRsol was isolated from h-gtl I by EcoRI digestion and was subcloned into the EcoRI cloning site in the mammalian expression vector pZEM229R (Zymogenetics Inc, Seattle, WA) to produce pZEMGMRso1. Sequencing of the insert in pZEM229R confirmed identity with the published GMRsol sequence.") The GMRtm clone was amplified in X-gtl 1 by polymerase chain reaction (PCR) with 5' and 3' primers that introduced a 5' terminal Xho I restriction enzyme site and a 3 ' terminal Xba I restriction enzyme site. This allowed subcloning into the Xho I-Xba I cut mammalian expression vector pDx (Zymogenetics) to produce pDGMRtm. The entire PCR-amplified product was sequenced in pDGMRtm in both directions to verify that PCR had not introduced inadvertent mutations.
pZEMGMRsol and pDGMRtm were transfected seperately into baby hamster kidney (BHK) cells by the calcium phosphate method." Clonal cell lines stably expressing GMRsol or GMRtm were established by selection of methotrexate-resistant colonies followed by expansion and amplification in increasing concentrations of methotrexate and screening of clones with '2SI-GM-CSF receptorbinding assays. Stable cell lines were maintained in RPMI 1 6 4 W 10% fetal calf serum/] % antibiotic-antimycotic solution.
I-GM-CSF receptor-binding assays. Cell-associated GM-CSF receptor-binding assays, which entail determining binding characteristics on the surface of intact receptor-bearing cells, were performed as previously described." The soluble GM-CSF receptorbinding assay was modified from the technique described by DiPersi0 et al. ' 7 Briefly, GMRsol-containing solution was incubated in receptor-binding buffer (RPMI 1640/1% bovine serum albumin [BSA]/25 mmol/L HEPES, pH 7.4) with '"I-GM-CSF (New England Nuclear/DuPont Inc, Mississauga, ON) in the absence or presence of an excess (greater than 50-fold) of unlabeled GM-CSF (final reaction volume, 50 pL). The specific activity of the '*'I-GM-CSF (76.9 to 110 pCi/bg) was determined by the manufacturer and was not independently verified. After I hour at room temperature, 50 /.LL of ice-cold buffer containing BSAhovine IgG (each at 20 mg/mL in receptor-binding buffer) was added, followed by 100 /.LL of icecold buffer containing 50% (wt/vol) polyethylene glycol-6000 (PEG-6000). The entire mixture was chilled on ice for 15 minutes and then layered over 1 0 0 pL of cold dibuty1:dinonyl (90:lO) phthalate oil in 400-pL Eppendorf tubes. GMRS~~/'*~I-GM-CSF complexes, preferentially precipitated by PEG-6000, were pelleted through the o i l by centrifugation at 12,000 rpm for S minutes at 4°C and the receptor-bearing pellets were cut from the bottoms of the tubes. Radioactivity in the pellet and supernatant from each tube was measured by crystal scintillation counting (efficiency, 75%).
Analysis of the binding data according to Scatchardi4 was performed using the EBDA and LIGAND software packages (ElsevierBiosoft Inc, Cambridge, UK). To circumvent the limitations of Scatchard analysis in determining the binding constants of lowaffinity receptors, binding data were also analyzed according to Segel.I5 In these experiments, receptor-containing samples were incubated with one of two fixed, known concentrations of 'Z51-GM-CSF in the absence or presence of serial concentrations of unlabeled GM-CSF, acting as a competitor for receptor occupancy. The specifically bound radioactivity was determined at each concentration of unlabeled GM-CSF for both of the fixed concentrations of Iz5I-GM-CSF. The data for each of the fixed concentrations of '*'I-GM-CSF were plotted, as outlined previously,16 as the inverse of the specifically bound counts per minute (cpm) against the concentration of unlabeled GM-CSF. Extrapolation of the best-fit curves (determined in the CricketGraph software program [Cricket Software, Malvern, PA]) for each of the concentrations of Iz5I-GM-CSF determines a point of intersection of the curves that can be extended to the x-axis to yield -dissociation constant (kd).
GMRsol purt$cation. A ligand affinity column was constructed by covalently reacting recombinant human GM-CSF via linker arms to derivatized agarose beads (Affi-Gel 15; BioRad Inc, Richmond, CA) according to the manufacturer's instructions. Unreacted sites on the beads were blocked with 0.5 m o m glycine/phosphate-buffered 6 GMRtrn, Kd-13.9 +/-l .4nM In fractions no. 4 and 5 "hot alone" cpm were extrememly high, and no competition was shown in "hot+ cold," suggesting an overwhelming excess of receptor. This was confirmed by dilution experiments in which a 50-fold dilution of these fractions was required to bring competition into the cpm range of all other fractions. Thus, results for these two fractions represent cpm specifically bound at 50-fold dilution x 50. Therefore, the graph cannot be considered representative of the exaH.rMiod receptor molecules in each fraction, but it is an accurate representation of the position of the peak of activity and fairly shows the large excess of material in fraction no. 4 over other fractions.
saline. Tissue-culture supernatant (approximately 200 mL) conditioned by the pZEMGMRso1-transfected cell lines was passed over the column at 4°C at a rate of 10 to 20 mLh.. After washing the column with at least 10 column volumes of 0.5 m o m glycine/ phosphate-buffered saline (pH 7.4) to remove nonabsorbed material, the receptor was eluted in 500-pL fractions using 0.1 m o m glycine (pH 2.5). The eluted fractions were neutralized immediately by collection into 25 pL of 1 m o m Tris (pH 8.0). The receptor content of each fraction was monitored by the PEG receptor-binding assay described above.
Preparation of metabolically labeled GMRsol. pZEMGMRsoltransfected cell lines were metabolically labeled for 36 to 48 hours by incubation in cysteine-methionine-free RPM1 164015% dialyzed fetal calf serum/l% antibiotic-antimycotic solution containing 40 pCi/mL of 35s cysteine-methionine (New England NuclearDuPont, Laval, QU). The labeled tissue-culture supernatant was purified over the GM-CSF affinity column as described.
Enzymatic deglycosylation of GMRsol. Metabolically labeled GMRsol was purified using the GM-CSF affinity column. Receptorcontaining fractions (nos. 3 to 10) were pooled, dialyzed against deionized water, and then lyophilized. For removal of 0-linked carbohydrates, the lyophylized material was resuspended in 1 mmoU L calcium acetate120 mmom Tris maleate (pH 6)/10 mmol/L Dgalactono-y-iactone/2 U/mL neuraminidase (final reaction volume, 20 pL; Genzyrne) and incubated for 1 hour at room temperature. The reaction volume was then doubled with the maintenance of existing constituent concentrations and the addition of 1 % NP40/ 0.1% sodium dodecyl sulfate/l pL 0-glycanase (Sigma, St Louis, MO), and the reaction was continued at room temperature overnight. For removal of N-linked carbohydrates, the lyophilized material was resuspended in 1 0 0 mmol/L NaPOJ50 mmol/L EDTA/l% NP40/ 0. I % sodium dodecyl sulfatell % &mercaptoethanol to a volume of 20 pL and denatured by boiling for 5 minutes. Endoglycosidase-F (7 pL; Boehringer Mannheim Inc. Laval, QV) was then added, and the mixture was deglycosylated overnight at 37°C.
BM co/ony$orming nssnvs. Human BM was obtained from informed volunteers and was density-seperated on Ficoll-Hypaque. Low-density cells were depleted of adherent cells by overnight incubation in plastic flasks. Cells (IO') were plated as previously described," and the cultures were incubated at 37°C in a fully humidified atmosphere containing 5% COz for 14 days; at which time, colonies were enumerated by inverted microscopy.
RESULTS
Comparison of the binding characteristics qf GMRsol and GMRtm. Receptor-binding assays were performed with BHK cells stably transfected with and expressing GMRtm and with conditioned medium from supernatant conditioned by BHK cells stably transfected with pZEMGMRsol. The experiments were performed to document the presence of a soluble GM-CSF-binding constituent in pZEMGMRsolconditioned media and to determine and directly compare the dissociation constants (kd) of both the soluble and transmembrane forms of the GM-CSF receptor a subunit. Performance of the assays for Scatchard analysis did not attain receptor saturation; therefore, Dixon analysis was used, as described in Materials and Methods, to estimate the affinity of unlabeled GM-CSF for the soluble and membrane-associated receptor. Figure I shows this method of data analysis and shows that GM-CSF-binding activity was indeed present in the conditioned media (Fig I , bottom panel) . The analysis showed that the kd of GM-CSF for GMRsol was 3.8 2 2.5 nmolk (range, 1 .O to 7.1 nmolk; n = 3). This value was reproducibly lower than the kd of GM-CSF for GMRtm (13.9 t 1.4 nmolk; range. 12.4 to 15.8 nmolk; n = 3; see Fig I , top panel) . It must be remembered that the binding assay for GMRsol allows determination of the binding characteristics in solution, whereas that for GMRtm determines the characteristics of the binding interaction on the surface of an intact cell. The value of the dissociation constant for GMRsol was still substantially higher than that which we determined for the native high-affinity GM-CSF receptor on HL60 cells (l45 pmolk; data not shown).
PuriJication of CMRsol. To define more clearly the biochemical properties of GMRsol, we felt it was necessary to purify and concentrate GMRsol from the crude tissue-culture supernatant. To this end, a GM-CSF ligand affinity column was constructed. Tissue-culture supernatant, conditioned by recombinant GMRsol-producing cell lines, was passed over the column, and the column was eluted with low-pH buffer as described in Materials and Methods. Figure 2 shows that, when receptor-binding assays were performed on the eluted fractions, a major peak of binding activity was recovered in fraction no. 4. This result suggested that a significant purification of GMRsol had been achieved. This distribution of binding activity in eluted fractions proved to be highly reproducible with subsequent use of the column.
For purposes of interpretation of all further experiments using GMRsol, a standard protocol for preparation and use of GMRsol was established. It was determined that 200 mL of GMRsol-conditioned medium could be virtually completely depleted of GMRsol-binding activity. The column was loaded with this volume of conditioned medium, and the column was eluted as described. As shown in Fig 2, we considered fraction no. 4 to contain 65% of the total eluted binding activity in U400 of the original volume. Therefore, we considered fraction no. 4 to represent a 260-fold concen-SOLUBLE GM-CSF RECEPTOR tration of GMRsol now dissolved in neutralized elution buffer (260 X GMRsol/l00 mmol/L glycinebo mmol/L Tris [pH 7.51). Aliquots of fraction no. 4 were used in all subsequent experiments expressed as a percentage of the final volume in the experiment. As a control in all experiments, aliquots of an elution fraction showing no binding activity, expressed as a percentage of the final volume in the experiment, were included (Ox GMRsoV100 mmol/L glycinel50 mmol/L Tris [pH 7.51). Therefore, the remainder of the report refers to "260x GMRsoI" and the "control buffer."
To assess the degree of purification which had taken place, aliquots of selected fractions were size-fractionated by polyacrylamide gel electropheresis (PAGE) under reducing conditions. Proteins were detected by silver stain. Figure 3 shows that a substantial purification had taken place, in that only two protein species could be visualized. A prominent 69-kD band (considered to be BSA) that was detected in fraction no. 1 decreased substantially in intensity in subsequent fractions and was virtually absent by fraction no. 4. However, binding activity was absent in fraction no. 1 and was maximal in fraction no. 4. Significantly, a protein band of about 60 kD appeared in fraction no. 4, corresponding to the peak of binding activity.
To confirm that the 60-kD band corresponded to the soluble receptor, the GMRsol-expressing cell line was metabolically labeled with 3sS-cysteine/methionine ("S-cyshet). Under these conditions, tissue-culture additives, such as BSA, would remain unlabeled. Labeled tissue-culture supernatant was purified over the GM-CSF affinity column, and binding assays were performed on eluted fractions. The same pattern of binding was obtained as shown in Fig 2, with a peak of binding activity in fraction no. 4. Aliquots of fractions no. I , 4, and 8 were size-fractionated by PAGE, followed by autoradiography of the fixed, dried gel. Figure 4 shows the appearance of a 55-to 60-kD radiolabeled band in the autoradiogram. The radiolabeled species was present in parallel with and in proportionate intensity to binding activity. This radiolabeled constituent migrated in precisely the same size range as the band shown by silver stain in Fig  3. Both the radiolabeled constituent and the band detected by silver stain appeared in parallel with the peak of binding activity.
Enzymatic deglycosylation of GMRsol. Although the primary amino acid sequence of GMRsol predicts a molecular weight (MW) of approximately 40 kD, the extracellular domain of the GM-CSF receptor a chain contains l l potential sites for the addition of N-linked sugars.' The presence of carbohydrate would increase the MW of the receptor above that predicted on the basis of amino acid sequence alone. To assess the extent of glycosylation of the 60-kD protein species, which was appearing in parallel with GM-CSFbinding activity, supernatant conditioned by the metabolically labeled pZEMGMRsol cell line was purified using a GM-CSF-affinity column and was then enzymatically deglyosylated to remove 0-linked or N-linked sugars. Metabolically labeled and immunoprecipitated recombinant GM-CSF was included as a control to judge the completeness of the deglycosylation reactions. GM-CSF was chosen as a control because of our previous experience in defining the carbohy- drate modification of GM-CSF.lR Figure 5 shows that treatment with 0-glycanase decreased the MW of the putative soluble receptor by no more than 5 k D . The MW of GM-CSF was decreased in keeping with our previous determinations of the degree of 0-linked glycosylation of GM-CSF." On the other hand, removal of N-linked sugars with Endoglycosidase-F resulted in a significant reduction in the MW of the band presumed to represent the receptor with the appearance of a prominent, sharp band of approximately 40 kD. The GM-CSF control showed a reduction in size in keeping with the known N-linked carbohydrate content of GM-CSF." Thus, the MW of the deglycosylated component believed to represent GMRsol corresponded very closely, if not exactly, to the MW that would be predicted on the basis of the amino acid sequence of GMRsol.
Ability of GMRsol to compete for ligand with cell sufaceanchored GM-CSF receptors. To begin to explore the biologic potential of GMRsol, aliquots of 260 X GMRsol were used as competitor in '251-GM-CSF receptor-binding assays, in which the sources of membrane-anchored receptor were (1) our BHK cell lines stably expressing GMRtm, (2) the high-affinity GM-CSF receptor as expressed on the human leukemic cell line HL60, and (3) the high-affinity GM-CSF receptor as expressed on human neutrophils. 
+ * +
so in a concentration-dependent manner. This result is most clearly shown in Fig 7B, which shows a Scatchard analysis of a series of GM-CSF receptor-binding experiments performed on human neutrophils in the absence or presence of serial dilutions of GMRsol. As the amount of GMRsol was increased, the slope of the curve (-Ikd) decreased. whereas the x-intercept (no.of receptors per cell) remained constant. These results were indicative of the presence of a successful competitor for the ligand. Data from the individual binding experiments performed on human neutrophils in the absence or presence of GMRsol were pooled using the LIGAND software program and were used to generate a cumulative dissociation constant and number of receptors per cell at each concentration of GMRsol. These results, shown in Table 1 , numerically demonstrate the kinetically competitive nature of GMRsol shown in Fig 7B. Effect of GMRsol on the biologic activity of GM-CSF. Although our data showed that GMRsol can act as a competitor for the ligand in our receptor-binding assay, even against the higher affinity native GM-CSF receptors, the more relevant question was whether or not GMRsol would modulate the biologic activity of GM-CSF in an in vitro assay. To explore this question, serial dilutions of GMRsol were added to human BM colony-forming assays performed in the presence of a constant amount of recombinant human GM-CSF, known to stimulate half-maximal colony growth. Appropriate controls were included in each experiment to account for any stimulatory or inhibitory activity inherent to the GMRsol diluent. Figure 8 shows that GMRsol was able to antagonize the biologic activity of GM-CSF in a concentration-dependent manner.
DISCUSSION
We have cloned, expressed, and partially purified the soluble form of the GM-CSF receptor a subunit. This purified preparation has allowed us to define some of the biochemical and biologic characteristics of the soluble receptor in vitro. Our experiments have clearly shown that the GMRsol cDNA encodes a soluble GM-CSF-binding protein. In that we have been able to evaluate quantitatively the basic ligand binding characteristics of GMRsol, our results extend the work of Raines et al.? who first showed that GMRsol was capable of binding to GM-CSF in solution. This evaluation was facilitated by the use of Dixon analysis of the binding data, wherein the affinity of the unlabeled ligand for GMRsol (3.8 % 2.5 nmol/L) was determined. In addition, our experiments indicated that GMRsol binds to GM-CSF with a reproducibly higher affinity than GMRtm. However, direct comparison of the affinities of GMRsol and GMRtm must be made with caution. The dissociation constant of GMRsol was determined in a soluble receptor-binding assay, whereas that for GMRtm was determined with GMRtm anchored on the surface of an intact cell. Dipersio et al'? have shown that solubilization of the GM-CSF receptor from the cell membrane before determining the dissociation constant significantly alters the measured affinity. One possible explanation for this difference in affinities is the greater degree of freedom for intermolecular interaction afforded two molecules (GMRsol and GM-CSF) in solution. In comparison, the binding of GM-CSF to GMRtm may be hampered by the relatively fixed position of GMRtm and the possible interference of neighboring cell surface molecules in such a way as to reduce the on-rate appreciably, thereby reducing the rigand equilibrium affinity constant. It is also possible, although unlikely, that inherent structural differences between GMRsol and GMRtm, perhaps arising from the unique 16 amino acid carboxyl-terminal tail of GMRsol, might contribute to the difference in affinity. However, we can currently offer no data to support the existence of any structural differences, volume, 26OxGMRsol added t o constitute 25% of the final reaction volume (HOT+GMRsol), or a r50-fold excess of unlabeled GM-CSF. Background cpm were determined as cell-associated counts remaining after incubation of cells with '%GM-CSF in the presence of excess unlabeled GM-CSF. Specifically bound cpm were determined as the difference between HOT value and HOT+COMPETITOR after subtraction of background cpm. Experimental points were performed in duplicate.
apart from membrane anchoring, between the two receptor forms, and this notion remains purely speculative. Although it is intriguing to wonder if the affinity differences between GMRsol and GMRtm are physiologically significant, given the limitations of our experimental techniques, it is probably only legitimate to state that the affinities of GMRsol and GMRtm for GM-CSF are similar.
As expressed in BHK cells, GMRsol would appear to exist as a 55-to 60-kD glycoprotein. Binding experiments performed on fractions collected from our GM-CSF affinity column had shown that a peak of binding activity was present in fraction no. 4 and that this peak of binding activity corresponded with the appearance of a 55-to 60-kD band on silverstained polyacrylamide gels. Metabolic labeling experiments confirmed that this 55-to 60-kD species was produced by cells transfected with the GMRsol cDNA. Finally, deglycosylation experiments showed that a substantial portion of the MW of the putative receptor was contributed by N-linked carbohydrate and a small amount of 0-linked carbohydrate. This degree of glycosylation was in keeping with the number of potential sites of N-linked glycosylation encoded by the GMRsol cDNA9 and with the data of Shibuya et all9 regarding the degree of N-linked glycosylation of GMRtm. Removal of the carbohydrate reduced the size of the band presumed to correspond to the GMRsol protein to that predicted by the GMRsol cDNA. The deglycosylation experiments provided perhaps the most compelling evidence that the 55-to 60-kD species that appears in parallel with the peak of binding activ- ity eluted from the ligand affinity column is indeed GMRsol. This size determination is also in good agreement with the data of Sasaki et a]'" who used an affinity-labeling technique to identify a 62-kD soluble GM-CSF-binding protein in the For each dilution of GMRsol, n = 2 to 5 experiments except for GMRsol = le-0.5, where n = 1.
'*O1
BROWN ET AL forces the question of what was the concentration of GMRsol being used in our experiments and how, if at all, did this concentration range reflect normal physiology? Unfortunately it has not been possible to obtain accurate estimates of the concentrations of GMRsol present in vivo, and our inability to eliminate the residual BSA, even after ligandaffinity column purification, without losing the biologic activity of GMRsol precluded a chemical estimate of the concentration of GMRsol present in our purified preparation. Scatchard data or visualization of GMRsol protein by PAGE have provided only rough approximations of purified GMRsol concentration that would have yielded concentrations of receptor in the nanomolar to micromolar range in the competition assays we performed. Answers to the relevance of our findings to physiological conditions will require continued efforts to accurately quantitate recombinant GMRsol and also to determine the pericellular concentrations of GMRsol in vivo.
Whether the various soluble receptors act as agonists or antagonists also seems to depend on the role of the cytoplasmic domain of the a subunit in mediating successful signal transduction by the native receptor. For instance, the IL-6R and the CNTFR are composed of a ligand-specific a subunit and two P subunits (a homodimer of gp130 for the IL-6R and a heterodimer of the leukemia inhibitory factorbinding protein and gp130 for the CNTFR)." In each of these receptor complexes, the two P subunits seem to possess all the machinery needed for signal transduction and require the a subunit only to bring the complex together. The CNTFR a chain does not have a cytoplasmic domain, being linked to the membrane through a glycosyl-phosphatidyl inositol linkage"; the cyotplasmic tail of IL-6R a chain is also unneccesary for signal transduction.'3 It may not be surprising then that the soluble forms of the ILdR a chain and the CNTFR a chain can act as agoni~ts'~.'' by initiating the assembly of the P subunits into a signal transducing unit.
In contrast, current evidence suggests that the cytoplasmic tail of the GM-CSF receptor a chain has a substantial role in productive signal transduction." The L 5 R , which uses the same P subunit as the GM-CSF receptor, also requires the cytoplasmic tail of its ligand-specific a subunit for full biologic activity." It would be predicted then that soluble forms of these receptor a subunits could not act a s agonists. The data we have obtained, as presented in this report, are in agreement with that prediction. Full insight into the biologic potential of the interaction between GMRsol and the membrane-anchored GM-CSF receptor P subunit awaits reconstitution experiments in which GMRsol is coincubated with a cellular system expressing only the GM-CSF receptor P subunit. The test system would have to be capable of responding to GM-CSF if fully functional, high-affinity, oligomeric GM-CSF receptors were present. Such experiments would more clearly address whether GMRsol has any capacity to participate in the formation of high-affinity GM-CSF receptors and to contribute to successful GM-CSFmediated signal transduction. supernatant of a human choriocarcinoma cell line. On examination of the biologic capabilities of GMRsol, our experiments clearly show that GMRsol competes for GM-CSF binding with either isolated GMRtm or high-affinity receptors expressed on HL60 cells and on freshly isolated human neutrophils. Competition occured across a wide range of GM-CSF concentrations and was proportional to the concentration of GMRsol. In human BM colony-forming assays, this property of GMRsol was manifested as a concentration-dependent antagonism of GM-CSF activity.
In the past few years, it has become evident that variant soluble forms exist for most members of the cytokine receptor superfamily.' The soluble receptor invariably arises from an alteration of the low-affinity, ligand-specific subunit of the multisubunit, native receptor. The exact physiological role of these soluble cytokine receptors remains unclear. Heaney and Golde' have suggested three possible roles for soluble cytokine receptors: ( I ) as carrier molecules for their ligands, ( 2 ) as agonists in the normal signalling process of the ligand, and (3) as antagonists in the normal signalling process of the ligand. While providing known examples of the first two roles for soluble cytokine receptors, the authors appropriately wondered whether it would be possible for soluble low-affinity subunits to act as antagonists of high-affinity interactions between cytokines and native cytokine receptors. Our data show that such antagonism is, in fact, possible.
There may be several explanations for such antagonism. The first is that, given a high enough concentration, GMRsol could overcome the affinity differences by mass action. This
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